{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T14:12:31Z","timestamp":1769436751848,"version":"3.49.0"},"update-to":[{"DOI":"10.1002\/14651858.cd008074","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T00:00:00Z","timestamp":1515369600000}}],"reference-count":137,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008074.pub2","type":"journal-article","created":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T03:46:02Z","timestamp":1515383162000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation)"],"prefix":"10.1002","volume":"2018","author":[{"given":"Edoardo G","family":"Ostinelli","sequence":"first","affiliation":[{"name":"Universit\u00e0 degli Studi di Milano; Department of Health Sciences; Via Antonio di Rudin\u00ec 8 Milan Italy 20142"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salwan","family":"Jajawi","sequence":"additional","affiliation":[{"name":"Rotherham, Doncaster and South Humber NHS Trust; Department of Psychiatry; Rotherham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Styliani","family":"Spyridi","sequence":"additional","affiliation":[{"name":"Cyprus University of Technology; Department of Rehabilitation Sciences, Faculty of Health Sciences; 30 Archbishop Kyprianou Street Lemesos Cyprus 3036"},{"name":"Psychiatry - UK LLP; PO Box 329 Dewsbury West Yorkshire UK WF13 9DN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamlaj","family":"Sayal","sequence":"additional","affiliation":[{"name":"Cygnet Hospital Derby; Wyvern Locked Rehabilitation Unit; 100 City Gate London Road Derby UK DE24 8WZ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahesh B","family":"Jayaram","sequence":"additional","affiliation":[{"name":"Melbourne Neuropsychiatry Centre; Department of Psychiatry; University of Melbourne Melbourne Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,1,8]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD008074.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00213-006-0541-x","article-title":"Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol","volume":"188","author":"Andrezina","year":"2006","journal-title":"Psychopharmacology"},{"issue":"11","key":"10.1002\/14651858.CD008074.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1185\/030079906X148445","article-title":"Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study","volume":"22","author":"Andrezina","year":"2006","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0003|cit3","unstructured":"Bristol-Myers S A randomized, double-blind comparison of the efficacy and safety of aripiprazole intramuscular formula, haloperidol, or placebo in the treatment of acutely agitated patients with a diagnosis of schizophrenia or schizoaffective disorder http:\/\/www.Clinicalstudyresults.org\/ 2004"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0004|cit4","unstructured":"Citrome LL Vester-Blokland E Archibald D McQuade R Kostic D Pikalov A Benefits of a second dose of intramuscular (IM) aripiprazole to control agitation in patients with schizophrenia or bipolar I disorder Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada 2006"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0005|cit5","unstructured":"Currier GW Crandall D Archibald D Nyilas M Kostic D Pikalov A Intramuscular (IM) aripiprazole controls agitation in patients with schizophrenia or bipolar disorder without excessive sedation Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada 2006"},{"issue":"3","key":"10.1002\/14651858.CD008074.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/01.pra.0000271658.86845.81","article-title":"Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations","volume":"13","author":"Daniel","year":"2007","journal-title":"Journal of Psychiatric Practice"},{"issue":"Suppl.3","key":"10.1002\/14651858.CD008074.pub2-BIB0007|cit7","first-page":"S509","article-title":"Comparison of intramuscular aripiprazole and haloperidol with placebo in acutely agitated schizophrenia patients","volume":"15","author":"Dillenschneider","year":"2005","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0008|cit8","unstructured":"Dillenschneider A Oren D Marcus R Kostic D McQuade R Iwamoto T Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study 18th European College of Neuropsychopharmacology Congress; 2005 October 22-26, Amsterdam, Netherlands 2005"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0009|cit9","unstructured":"McQuade R Auby P Oren D Marcus R Kostic D Iwamoto T Intramuscular aripiprazole in acute schizophrenia: a double-blind, placebo-controlled comparison with IM haloperidol Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland Davos, Switzerland Elsevier Science Bv 2006 57 8"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0010|cit10","unstructured":"Oren D Marcus R Kostic D McQuade R Iwamoto T Archibald D Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26, Atlanta, Georgia, USA 2005"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0011|cit11","first-page":"499","article-title":"Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder","volume":"31","author":"Oren","year":"2005","journal-title":"Schizophrenia Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD008074.pub2-BIB0012|cit12","first-page":"451","article-title":"Non-inferiority of intramuscular aripiprazole versus intramuscular haloperidol for the treatment of agitation associated with schizophrenia\/schizoaffective disorder","volume":"33","author":"Oren","year":"2007","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0013|cit13","unstructured":"Yocca F Marcus R Oren D Manos G Carson W Iwamoto T Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26, Atlanta, Georgia, USA 2005"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0014|cit14","unstructured":"Bristol-Myers Squibb Randomized, double-blind, dose-ranging study of intramuscular aripiprazole in the treatment of acute agitation in patients with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder http:\/\/www.clinicalstudyresults.org\/ 2005"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0015|cit15","unstructured":"Daniel DG Stock EG Wilber CH Marcus RN Carson WH Jr Manos G Intramuscular aripiprazole in acutely agitated psychotic patients 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, New York, USA 2004"},{"issue":"Suppl.3","key":"10.1002\/14651858.CD008074.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"S261","DOI":"10.1016\/S0924-977X(04)80286-4","article-title":"Intramuscular aripiprazole treatment for acute agitation in patients with psychosis","volume":"14","author":"Gismondi","year":"2004","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0017|cit17","first-page":"77","article-title":"Intramuscular aripiprazole for the treatment of acute agitation accompanied with schizophrenia: Subanalysis of a double-blind controlled study to find the dosage","volume":"78","author":"Kungel","year":"2007","journal-title":"Nervenarzt"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0018|cit18","unstructured":"Kungel M Daniel D Stock E Wilber R Marcus R Carson W Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis Thematic conference of the World Psychiatric Association on \"Treatments in Psychiatry: an update\" Florence, Italy"},{"issue":"S1","key":"10.1002\/14651858.CD008074.pub2-BIB0019|cit19","first-page":"218","article-title":"Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis","volume":"3","author":"Kungel","year":"2004","journal-title":"World Psychiatry"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0020|cit20","unstructured":"Modell S Daniel D Stock E Wilber R Marcus R Carson W Intramuscular aripiprazole treatment for acute agitation in patients with psychosis XXIVth Collegium Internationale Neuro-Psychopharmacologicum Congress; 2004 June 20-24, Paris, France 2004"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1016\/j.eurpsy.2007.01.397","article-title":"Intramuscular aripiprazole for the treatment of acute agitation associated with schizophrenia: Sub-analysis of a double-blind, controlled, dose-ranging study","volume":"22","author":"Oren","year":"2007","journal-title":"European Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD008074.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4088\/JCP.v68n0115","article-title":"Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial","volume":"68","author":"Tran-Johnson","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0023|cit23","unstructured":"Yocca F Daniel D Stock E Oren D Marcus R Carson W Efficacy and safety of intramuscular aripiprazole treatment for acute agitation in patients with psychosis 43rd Annual Meeting of the American College of Neuropsychopharmacology; 2004 Dec 12-16; San Juan, Puerto Rico 2004"},{"issue":"2-3","key":"10.1002\/14651858.CD008074.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2016.07.017","article-title":"Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: A pragmatic double-blind randomized trial","volume":"176","author":"Kittipeerachon","year":"2016","journal-title":"Schizophrenia Research"},{"issue":"3","key":"10.1002\/14651858.CD008074.pub2-BIB0025|cit25","first-page":"198","article-title":"The effectiveness of aripirazole combined with clonazepam treated with agitation in schizophrenia","volume":"19","author":"Bao","year":"2007","journal-title":"Medical Journal of Chinese People's Health"},{"issue":"4","key":"10.1002\/14651858.CD008074.pub2-BIB0026|cit26","first-page":"261","article-title":"Aripiprazole treatment of agitation associated with schizophrenia] Google Translate","volume":"19","author":"\u9648\u8fdc\u5cad","year":"2009","journal-title":"Linchuang Jingshen Yixue Zazhi [\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7]"},{"issue":"9","key":"10.1002\/14651858.CD008074.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1017\/S1092852900014784","article-title":"The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia","volume":"11","author":"Cutler","year":"2006","journal-title":"CNS Spectrums"},{"issue":"6","key":"10.1002\/14651858.CD008074.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.biopsych.2008.07.033","article-title":"A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia","volume":"65","author":"Fleischhacker","year":"2009","journal-title":"Biological Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008074.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"103s","DOI":"10.1016\/S0924-9338(02)80465-5","article-title":"Controlled study of aripiprazole and haloperidol in schizophrenia","volume":"17","author":"Anutosh","year":"2002","journal-title":"European Psychiatry"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0030|cit30","doi-asserted-by":"crossref","unstructured":"Carson WH Ali M Saha AR Dunbar GC Ingenito G A double-blind, placebo-controlled trial of aripiprazole and haloperidol in patients with schizophrenia or schizoaffective disorder 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10-14; San Juan, Puerto Rico 2000","DOI":"10.1016\/S0924-977X(00)80358-2"},{"issue":"9","key":"10.1002\/14651858.CD008074.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4088\/JCP.v63n0903","article-title":"Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder","volume":"63","author":"Kane","year":"2002","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0032|cit32","unstructured":"Kane JM Ingenito G Ali M Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, Illinois, USA 2000"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0033|cit33","unstructured":"Kane JM Ingenito G Ali M Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA 2002"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0034|cit34","unstructured":"Eli Lilly Company Olanzapine versus aripiprazole in the treatment of acutely ill patients with schizophrenia Eli Lilly and Company Clinical Trial Registry 2004"},{"issue":"6","key":"10.1002\/14651858.CD008074.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/JCP.0b013e31818aaf6c","article-title":"Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia","volume":"28","author":"Kinon","year":"2008","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0036|cit36","unstructured":"NCT00103571 Olanzapine versus aripiprazole in the treatment of acutely ill patients with schizophrenia http:\/\/www.clinicaltrials.gov 2005"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0037|cit37","doi-asserted-by":"crossref","unstructured":"Stauffer V Kinon B Kollack-Walker S Chen L Sniadecki J Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8, Washington DC, USA 2008","DOI":"10.1016\/S0920-9964(08)70774-6"},{"issue":"7","key":"10.1002\/14651858.CD008074.pub2-BIB0038|cit38","first-page":"788","article-title":"Aripiprazole for schizophrenia combined magnesium valproate efficacy of impulse control disorders] Google Translate","volume":"38","author":"\u674e\u6811\u751f","year":"2009","journal-title":"Chongqing Medical Journal"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0039|cit39","unstructured":"Liang S A multi-center, randomized, double-blind study, comparing with risperidone, to evaluate the efficacy and safety of aripiprazole in the treatment of patients with schizophrenia http:,www.clinicaltrials.gov 2005"},{"issue":"14","key":"10.1002\/14651858.CD008074.pub2-BIB0040|cit40","first-page":"31","article-title":"\u4e19\u620a\u9178\u9541\u5bf9\u7cbe\u795e\u5206\u88c2\u75c7\u5174\u594b\u6fc0\u8d8a\u884c\u4e3a\u7684\u8f85\u52a9\u7597\u6548\u89c2\u5bdf","volume":"10","author":"\u5218\u6770","year":"2012","journal-title":"\u793e\u533a\u533b\u5b66\u6742\u5fd7"},{"issue":"11","key":"10.1002\/14651858.CD008074.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jpsychires.2007.05.002","article-title":"A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg\/day for the treatment of patients with acute exacerbations of schizophrenia","volume":"41","author":"McEvoy","year":"2007","journal-title":"Journal of Psychiatric Research"},{"issue":"2","key":"10.1002\/14651858.CD008074.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/YIC.0000000000000106","article-title":"Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia","volume":"31","author":"Citrome","year":"2016","journal-title":"International Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD008074.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/YIC.0000000000000154","article-title":"Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia: Erratum","volume":"32","author":"Citrome","year":"2017","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0044|cit44","first-page":"S359","article-title":"Efficacy of aripiprazole lauroxil, a new long-acting injectable atypical antipsychotic, across three geographic regions","volume":"39","author":"Hard","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0045|cit45","unstructured":"Meltzer HY Nasrallah HA Risinger R Du Y Zummo J Corey L Aripiprazole lauroxil: an innovative long-acting injectable in development for treatment of schizophrenia 168th Annual Meeting of American Psychiatric Association; Toronto, Canada; May 16-20, 2015 2015"},{"issue":"8","key":"10.1002\/14651858.CD008074.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.4088\/JCP.14m09741","article-title":"A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia","volume":"76","author":"Meltzer","year":"2015","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0047|cit47","unstructured":"NCT01469039 A study to evaluate the efficacy and safety of alks 9072 (also known as alks 9070) in subjects with schizophrenia http:\/\/ClinicalTrials.gov\/show\/NCT01469039 2011"},{"issue":"11","key":"10.1002\/14651858.CD008074.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.4088\/JCP.15m10467","article-title":"Effect of aripiprazole lauroxil on metabolic and endocrine profiles and related safety considerations among patients with acute schizophrenia","volume":"77","author":"Nasrallah","year":"2016","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.schres.2016.09.034","article-title":"Effect of patient age on treatment response in a study of the acute exacerbation of psychosis in schizophrenia","volume":"179","author":"Targum","year":"2017","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0050|cit50","unstructured":"Carson WH Saha AR Ali M Dunbar GC Ingenito G Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA Marathon Multimedia 2001"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0051|cit51","unstructured":"Carson WHJ Saha AR Ali M Dunbar GC Ingenito G Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA 2002"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S0920-9964(03)80511-X","article-title":"Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder","volume":"60","author":"Potkin","year":"2003","journal-title":"Schizophrenia Research"},{"issue":"7","key":"10.1002\/14651858.CD008074.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","article-title":"Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder","volume":"60","author":"Potkin","year":"2003","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0054|cit54","unstructured":"Saha A Carson W Ali M Dunbar G Ingenito G Efficacy and safety of aripiprazole and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder 7th World Congress of Biological Psychiatry; 2001 Jul 1-6; Berlin, Germany 2001"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD008074.pub2-BIB0055|cit55","first-page":"185","article-title":"Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder","volume":"53","author":"Yeung","year":"2002","journal-title":"Schizophrenia Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008074.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"102s","DOI":"10.1016\/S0924-9338(02)80463-1","article-title":"Aripiprazole and risperidone versus placebo in schizophrenia","volume":"17","author":"Yeung","year":"2002","journal-title":"European Psychiatry"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0057|cit57","unstructured":"Simpson G Mohammad AR Fauzia S Campaneau M Laska E Ninah R A comparison of rapid titration quetiapine and haloperidol in agitated adults in an emergency setting Proceedings of the 163rd Annual Meeting of the American Psychiatric Association; 2010 May 22-26; New Orleans, LA 2010"},{"issue":"1","key":"10.1002\/14651858.CD008074.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.schres.2005.12.857","article-title":"A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA)","volume":"84","author":"Tandon","year":"2006","journal-title":"Schizophrenia Research"},{"issue":"3","key":"10.1002\/14651858.CD008074.pub2-BIB0059|cit59","first-page":"325","article-title":"\u975e\u5178\u578b\u6297\u7cbe\u795e\u75c5\u836f\u5bf9\u7cbe\u795e\u5206\u88c2\u75c7\u60a3\u8005\u6fc0\u8d8a\u884c\u4e3a\u7684\u968f\u673a\u5bf9\u7167\u7814\u7a76","volume":"22","author":"\u738b\u7426","year":"2014","journal-title":"\u4e2d\u56fd\u5065\u5eb7\u5fc3\u7406\u5b66\u6742\u5fd7"},{"issue":"03","key":"10.1002\/14651858.CD008074.pub2-BIB0060|cit60","first-page":"191","article-title":"Clinical observation of magnesium valproate sustained release tablets adjuvant treatment of schizophrenia attacks","volume":"21","author":"\u9889\u745e","year":"2011","journal-title":"\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0061|cit61","unstructured":"Daniel DG Crandall D Manos G McQuade RD Gutierrez-Esteinou R Pikalov AA Transitioning from intramuscular (IM) to oral aripiprazole in patients with schizophrenia Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada 2006"},{"issue":"3","key":"10.1002\/14651858.CD008074.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"S469","DOI":"10.1016\/S0924-977X(10)70691-X","article-title":"Intramuscular aripiprazole versus injectable haloperidol in treatment of acute psychotic agitation","volume":"20","author":"Istikoglou","year":"2010","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0063|cit63","unstructured":"Abilify (Aripiprazole). US full prescribing information http:\/\/otsuka-us.com\/products\/Documents\/Abilify.PI.pdf?_ga=1.242215874.1724823722.1491413596"},{"issue":"4","key":"10.1002\/14651858.CD008074.pub2-BIB0064|cit64","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007445.pub2","article-title":"Chlorpromazine for psychosis-induced aggression or agitation","author":"Ahmed","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD008074.pub2-BIB0065|cit65","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009412","article-title":"Risperidone for psychosis induced aggression or agitation","author":"Ahmed","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1192\/bjp.185.1.63","article-title":"Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting: Pragmatic randomised trial of intramuscular lorazepam v. haloperidol plus promethazine","volume":"185","author":"Alexander","year":"2004","journal-title":"British Journal of Psychiatry"},{"issue":"7068","key":"10.1002\/14651858.CD008074.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0068|cit68","unstructured":"American Psychiatric Association Practice guideline for the treatment of patients with schizophrenia, 2nd Edition Practice guideline for the treatment of patients with schizophrenia 2006"},{"issue":"2","key":"10.1002\/14651858.CD008074.pub2-BIB0069|cit69","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003729.pub2","article-title":"Olanzapine IM or velotab for acutely disturbed\/agitated people with suspected serious mental illnesses","author":"Belgamwar","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD008074.pub2-BIB0070|cit70","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002304.pub2","article-title":"Clotiapine for acute psychotic illnesses","author":"Berk","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD008074.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1176\/ps.50.12.1553","article-title":"Contemporary practices in managing acutely violent patients in 20 psychiatric emergency rooms","volume":"50","author":"Binder","year":"1999","journal-title":"Psychiatric Services"},{"issue":"7108","key":"10.1002\/14651858.CD008074.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0073|cit73","first-page":"235","article-title":"4.2.1 Antipsychotic drugs","volume-title":"BNF 67 March-September 2014","author":"BNF","year":"2014"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0074|cit74","volume-title":"British National Formulary","author":"British National Formulary","year":"2017"},{"issue":"4","key":"10.1002\/14651858.CD008074.pub2-BIB0075|cit75","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"issue":"5","key":"10.1002\/14651858.CD008074.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/archpsyc.59.5.441","article-title":"A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia","volume":"59","author":"Breier","year":"2002","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD008074.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/01688638908400888","article-title":"Development of a scale for assessment of agitation following traumatic brain injury","volume":"11","author":"Corrigan","year":"1989","journal-title":"Journal of Clinical and Experimental Neuropsychology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008074.pub2-BIB0078|cit78","first-page":"3S","article-title":"Clinical practice guidelines: Treatment of schizophrenia","volume":"50","author":"Addington","year":"2005","journal-title":"Canadian Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD008074.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1192\/pb.18.3.138","article-title":"Drug management of disturbed behaviour by psychiatrists","volume":"18","author":"Cunnane","year":"1994","journal-title":"Psychiatric Bulletin"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0080|cit80","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town Cape Town The Cochrane Collaboration 2000"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0081|cit81","unstructured":"Deeks JJ Higgins JPT Altman DG (editors) Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"issue":"6","key":"10.1002\/14651858.CD008074.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"issue":"19","key":"10.1002\/14651858.CD008074.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"12","key":"10.1002\/14651858.CD008074.pub2-BIB0084|cit84","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003441.pub3","article-title":"'As required' medication regimens for seriously mentally ill people in hospital","author":"Douglas-Hall","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD008074.pub2-BIB0085|cit85","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009922.pub2","article-title":"De-escalation techniques for psychosis-induced aggression or agitation","author":"Du","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"13","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD008074.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0088|cit88","unstructured":"US Federal Drug Administration CDER Application number: NDA 21-436\/S-002 (accessed 5 April 2017) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2004\/021436Orig1s002.pdf 2004"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/0306624X9303700406","article-title":"Homicide between inpatients in a mental institution ward","volume":"37","author":"Ferracuti","year":"1993","journal-title":"International Journal of Offender Therapy and Comparative Criminology"},{"issue":"7","key":"10.1002\/14651858.CD008074.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD008074.pub2-BIB0091|cit91","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003079.pub3","article-title":"Benzodiazepines for psychosis-induced aggression or agitation","author":"Gillies","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD008074.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0093|cit93","doi-asserted-by":"crossref","unstructured":"Guy W Clinical Global Impression The ECDEU Assessment Manual for Psychopharmacology-Revised, National Institute of Mental Health 1976 217-21","DOI":"10.1037\/e591322011-001"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0095|cit95","unstructured":"Higgins JPT Green S (editors) Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0096|cit96","unstructured":"Higgins JPT Altman DG Sterne JAC (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"issue":"4","key":"10.1002\/14651858.CD008074.pub2-BIB0097|cit97","first-page":"1","article-title":"Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro-Brazil: a prevalence study","volume":"2","author":"Huf","year":"2002","journal-title":"BMC Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD008074.pub2-BIB0098|cit98","first-page":"1","article-title":"TREC-Rio trial: a randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms","volume":"2","author":"Huf","year":"2002","journal-title":"BMC Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD008074.pub2-BIB0099|cit99","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005146.pub3","article-title":"Haloperidol plus promethazine for psychosis-induced aggression","author":"Huf","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD008074.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2141.2009.07707.x","article-title":"Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials","volume":"146","author":"Hutton","year":"2009","journal-title":"British Journal of Haematology"},{"issue":"4","key":"10.1002\/14651858.CD008074.pub2-BIB0101|cit101","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000525.pub3","article-title":"Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses","author":"Jayakody","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0102|cit102","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"issue":"2","key":"10.1002\/14651858.CD008074.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"261-76","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophrenia Bulletin"},{"issue":"12","key":"10.1002\/14651858.CD008074.pub2-BIB0104|cit104","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002830.pub3","article-title":"Droperidol for psychosis-induced aggression or agitation","author":"Khokhar","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0105|cit105","doi-asserted-by":"crossref","unstructured":"Khushu A Powney MJ Haloperidol for long-term aggression in psychosis Cochrane Database of Systematic Reviews 2016 10.1002\/14651858.CD009830.pub2","DOI":"10.1002\/14651858.CD009830.pub2"},{"issue":"1","key":"10.1002\/14651858.CD008074.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0022-3565(25)10600-9","article-title":"7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity","volume":"274","author":"Kikuchi","year":"1995","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"11","key":"10.1002\/14651858.CD008074.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.biopsych.2005.10.020","article-title":"Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology","volume":"59","author":"Leon","year":"2006","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of brief psychiatric rating scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD008074.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatrica Scandinavica. Supplementum"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0111|cit111","first-page":"15","volume-title":"Collins Compact English Dictionary","author":"Makins","year":"1994"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD008074.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2165\/00023210-200216110-00008","article-title":"Aripiprazole","volume":"16","author":"McGavin","year":"2002","journal-title":"CNS Drugs"},{"issue":"9263","key":"10.1002\/14651858.CD008074.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0140-6736(00)04337-3","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials","volume":"357","author":"Moher","year":"2001","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD008074.pub2-BIB0115|cit115","first-page":"327","article-title":"Treatment of acute agitation in psychotic disorders","volume":"26","author":"Mohr","year":"2005","journal-title":"Neuro Endocrinology Letters"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1477-7525-9-18","article-title":"Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room","volume":"9","author":"Montoya","year":"2011","journal-title":"Health Quality Life Outcomes"},{"issue":"3","key":"10.1002\/14651858.CD008074.pub2-BIB0117|cit117","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002084.pub2","article-title":"Containment strategies for people with serious mental illness","author":"Muralidharan","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0118|cit118","unstructured":"NHS prescription services http:\/\/www.nhsbsa.nhs.uk\/prescriptions"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0119|cit119","unstructured":"National Institute for Clinical Excellence Violence and aggression: short-term management in mental health, health and community settings nice.org.uk\/guidance\/ng10 2015"},{"issue":"7","key":"10.1002\/14651858.CD008074.pub2-BIB0120|cit120","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009377.pub3","article-title":"Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation)","author":"Ostinelli","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"issue":"7265","key":"10.1002\/14651858.CD008074.pub2-BIB0122|cit122","first-page":"865","article-title":"Rapid tranquilization of violent or agitated people in psychiatric emergency settings: A pragmatic randomised controlled trial of intramuscular olanzapine versus intramuscular haloperidol plus promethazine","volume":"335","author":"Raveendran","year":"OCT 2007","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD008074.pub2-BIB0123|cit123","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001163","article-title":"Seclusion and restraint for people with serious mental illnesses","author":"Sailas","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1192\/apt.bp.109.007310","article-title":"Management of acute agitation in psychosis: an evidence-based approach in the USA","volume":"17","author":"Schleifer","year":"2011","journal-title":"Advances in Psychiatric Treatment"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0125|cit125","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"8","key":"10.1002\/14651858.CD008074.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavica. Supplementum"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0128|cit128","unstructured":"Sterne JAC Egger M Moher D (editors) Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"issue":"15","key":"10.1002\/14651858.CD008074.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2165\/00003495-200464150-00010","article-title":"Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder","volume":"64","author":"Swainston Harrison","year":"2004","journal-title":"Drugs"},{"issue":"2","key":"10.1002\/14651858.CD008074.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1176\/ajp.139.2.212","article-title":"Assaultive behavior among chronic inpatients","volume":"139","author":"Tardiff","year":"1982","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1176\/ajp.142.8.960","article-title":"Assaultive behavior among psychiatric outpatients","volume":"142","author":"Tardiff","year":"1985","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008074.pub2-BIB0132|cit132","unstructured":"Toal F Roberts K Clozapine for people with psychosis-induced aggression or agitation Cochrane Database of Systematic Reviews 2012"},{"issue":"5","key":"10.1002\/14651858.CD008074.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based intervention in health and health care: A systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"issue":"11","key":"10.1002\/14651858.CD008074.pub2-BIB0134|cit134","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010190","article-title":"Loxapine inhaler for psychosis-induced aggression or agitation","author":"Vangala","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD008074.pub2-BIB0135|cit135","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009801","article-title":"Quetiapine for psychosis-induced aggression or agitation","author":"Wilkie","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD008074.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"},{"issue":"4","key":"10.1002\/14651858.CD008074.pub2-BIB0137|cit137","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008074","article-title":"Aripiprazole for psychosis-induced aggression or agitation","author":"Pagadala","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD008074.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T13:15:47Z","timestamp":1751202947000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008074.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,1,8]]},"references-count":137,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008074.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,8]]}}}